ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.

Skye Bioscience Inc (SKYE) reports promising weight loss results and strategic R&D collaborations, despite challenges in dosing and delivery.

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability ...

ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after ...

The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting ...

As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...

Roche announces positive phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity: Basel Saturday, March 7, 2026, 09:00 Hrs [IST ...

A MOTHER has revealed that her glow-up “needs to be studied” after she slimmed down while on Mounjaro. Mollie, a mum-of-four ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.

The Citizens Life Sciences Conference 2026 March 11, 2026 10:45 AM EDTCompany ParticipantsHelen Torley - President, ...

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard ...